Search INDV
Indivior Pharmaceuticals, Inc.
Nasdaq · CIK 1625297
Last close35.71
Daily change+0.33 (0.93%)
10 Years gain+83.60%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
INDV · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
56.8Momentum
n/aAcceleration
n/aConfidence
70.0Annual Revenue4
Quarterly Revenue8
Annual CFO4
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth12.1 / 25
Quality17.2 / 25
Capital Efficiency20.0 / 20
Balance Sheet4.6 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.09 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 0.8%.
Key Metrics
Revenue Growth TTM10.38%OK
Revenue CAGR 3Y11.2%OK
Gross Margin82.37%OK
Operating Margin32.29%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC575.04%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-0.8%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.24B | $994.00M | $262.00M | -$27.00M | -$93.00M | 80.23% | 21.15% | -7.51% | n/a | 128M |
| 2025 FY Dec 31, 2024 | $1.19B | $957.00M | $38.00M | $36.00M | $7.00M | 80.56% | 3.2% | 0.59% | n/a | 133M |
| 2025 FY Dec 31, 2023 | $1.09B | $919.00M | -$152.00M | -$300.00M | -$308.00M | 84.08% | -13.91% | -28.18% | n/a | 137M |
| 2025 FY Dec 31, 2022 | n/a | $750.00M | -$77.00M | -$4.00M | n/a | n/a | n/a | n/a | n/a | n/a |
| 2024 FY Dec 31, 2022 | $901.00M | $749.00M | n/a | n/a | n/a | 83.13% | n/a | n/a | n/a | 139M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.28B | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-051895, 0001628280-25-047530 |
| Revenue Growth TTM | 10.38% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-051895, 0001628280-25-047530 |
| Revenue CAGR 3Y | 11.2% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012237 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-012237 |
| Gross Profit CAGR 3Y | 9.89% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012237 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-051895, 0001628280-25-047530 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 82.37% | Gross Profit / Revenue | OK | 0001628280-26-051895, 0001628280-25-047530 |
| Operating Margin | 32.29% | Operating Income / Revenue | OK | 0001628280-26-051895, 0001628280-25-047530 |
| ROIC | 575.04% | NOPAT / Average Invested Capital | OK | 0001628280-26-051895, 0001628280-25-047530 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-051895 |
| Current Ratio | 0.84x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.46x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-051895 |
| Revenue per Diluted Share | $10.29 | Revenue / Diluted Shares | OK | 0001628280-26-051895, 0001628280-25-047530 |